Gradipore hires CEO after six-month search
25 September, 2003 by Melissa TrudingerSydney-based bioseparations specialist Gradipore (ASX:GDP) has named former investment banker Greg Pynt as its new CEO. Pynt, whose previous roles include being joint head of equity capital markets at Deutsche Bank as well as a stint at Intersuisse, replaced US-based Bob Lieb, who quit the CEO post in May.
Select Vaccines signs hep E deal with Genelabs
25 September, 2003 by Melissa TrudingerMelbourne-based Select Vaccines (ASX:SLT) has signed its first agreement, with Singapore diagnostics company Genelabs Diagnostics, to bring the recently formed company's hepatitis E rapid diagnostic test to market.
Peptech confident in J&J royalty dispute
25 September, 2003 by Melissa TrudingerPeptech (ASX:PTD) is confident of coming out on top in its dispute with Centocor and its parent company Johnson & Johnson, the company said today after announcing the initiation of formal arbitration proceedings against the US firms.
New project to tackle sheep genomics
25 September, 2003 by Graeme O'NeillIn a simpler age, before molecular genetics, CSIRO researchers developed SireSine, a contraption containing a large, waterproof wax crayon strategically mounted around a ram's chest, that allowed him to sign off on the backs of obliging ewes.
Biota in US agreement over SARS tests
24 September, 2003 by Graeme O'NeillBiota (ASX:BTA) has formed an agreement with two US government agencies -- the National Institute of Allergy and Infectious Diseases (NIAID) and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) -- to test the company's antiviral compounds for activity against the SARS virus.
Q-Pharm toasts success after first year in operation
24 September, 2003 by Tanya HollisQueensland's first Phase I clinical trials facility, Q-Pharm, has just celebrated its first birthday with almost 20 clinical trials under its belt already.
Solagran claims success in liver disease drug trials
24 September, 2003 by Tanya HollisBotanical biotech Solagran (ASX: SLA) has announced success in preliminary trials of a bioeffective compound for the treatment of liver diseases.
Epitan partners with pSivida in tanning drug project
24 September, 2003 by Tanya HollisA safe tan in a single injection is the aim of a new collaborative agreement between two Australian biotechnology companies.
Peptech gets green light for dog contraceptive
23 September, 2003 by Graeme O'NeillSydney peptide and protein therapeutics developer Peptech Ltd (ASX:PTD ) has announced that its fully owned subsidiary, Peptech Animal Health (PAH) has received approval to market its Suprelorin six-month contraceptive for dogs in Australia.
ATP Innovations signs MoU with CSU, Wagga Wagga
23 September, 2003 by Tanya HollisTechnology business commercialisation centre ATP Innovations has entered an agreement with Charles Sturt University and Wagga Wagga City Council to help put research on the track to market.
Acrux in major deal with Eli Lilly
23 September, 2003 by Tanya HollisMelbourne drug delivery systems developer Acrux has signed a major deal with global pharmaceutical group Eli Lilly and Company to commercialise its veterinary product line.
New study to explore genetics of eczema
22 September, 2003 by Tanya HollisA tri-state research collaboration is set to use sibling pairs to examine the genetic reasoning behind the most common form of eczema
CSIRO livestock researchers explore potential of new technologies
22 September, 2003 by Graeme O'NeillTwo animal-virus hunters at CSIRO are exploring the potential of advanced genetic and proteomics technologies to make more accurate and rapid diagnoses of viral diseases and other microbial infections of livestock.
Virax raises $3.4m
22 September, 2003 by Tanya HollisDevelopment-stage biotechnology company Virax Holdings (ASX: VHL) has raised $3.4 million in a capital raising aimed to progress its prostate cancer and HIV drug development programs.
New CEO at Peplin Biotech
22 September, 2003 by Tanya HollisBrisbane small molecule drug development company Peplin Biotech (ASX: PEP) today announced the appointment of its new chief executive.
